宫颈癌组织中HPV16 E6C基因变异的研究  

VARIATION ANALYSIS OF HPV 16 E6C GENE FROM CERVICAL CARCINOMA

作　　者：赵蔚明[1] 周亚滨[1] 权衡 栾怡[1] 齐眉[1] 贾继辉[1] 董杰德[1] 于修平[1] 

机构地区：[1]山东医科大学微生物学教研室

出　　处：《山东医科大学学报》1999年第4期280-281,共2页Acta Academiae Medicinae Shandong

基　　金：山东省科委科研基金!资助课题(96116530)

摘　　要：为探讨ＨＰＶ１６ 肿瘤相关抗原Ｅ６ 羧基端基因片段（Ｅ６Ｃ）在宫颈癌组织中的变异性以及采用Ｅ６Ｃ做为肿瘤治疗性疫苗抗原基因的可行性，采用ＰＣＲ方法自１８ 例单纯ＨＰＶ１６ ＤＮＡ 阳性的宫颈癌组织中扩增ＨＰＶ１６ Ｅ６ＣＤＮＡ，经单链构象多态性分析（ＳＳＣＰ）和ＤＮＡ序列测定法检测其基因变异性。ＳＳＣＰ分析结果显示，１８ 例宫颈癌组织中ＨＰＶ１６ Ｅ６ＣＤＮＡ 电泳条带与标准对照ＤＮＡ 条带一致，提示无基因变异现象存在，ＤＮＡ 序列测定也证实Ｅ６Ｃ编码区内无核苷酸突变。该研究证实采用ＨＰＶ１６ Ｅ６Ｃ端基因片段作为ＨＰＶ疫苗候选基因可行，为进一步研制ＨＰＶ１６ ＤＮＡTo explore the gene variation of HPV16 E6 C terminal gene fragment (E6C) and the feasibility of tumor vaccine candidate gene of the E6C, the authors amplified E6C DNA from HPV16 positive cervical carcinoma with the PCR. The states of alterations of E6C DNA were investigated with the single stranded conformational polymorphism analysis (SSCP) and confirmed by DNA sequencing. The results showed that the HPV 16 E6C sequencing from cervical carcinoma had no mutation, compared with the prototype E6 gene of HPV 16. This finding indicate that HPV16 E6 C terminal gene fragment from cervical carcinoma is relatively stable and can be used as a vaccine candidate gene for the therapy of HPV related cancers. The present result is the basis for further research on safe and effective HPV DNA vaccine.

关 键 词：乳头状瘤病毒 宫颈癌 基因突变 

分 类 号：R737.33[医药卫生—肿瘤]